Multicancer Early Detection Screening Improves Patient Outcomes
By Elana Gotkine HealthDay Reporter
FRIDAY, May 9, 2025 -- Annual multicancer early detection (MCED) screening with a single blood test provides more overall benefit than biennial MCED screening, according to a study published online May 8 in BMJ Open.
Brian Rous, M.B., B.Chir., Ph.D., from Cambridge University in the United Kingdom, and colleagues estimated the effect of screening with an MCED test at different intervals (emphasis on annual and biennial screening) on cancer stage at diagnosis and mortality end points. Two sets of tumor growth scenarios were investigated: fast (two to four years in stage I) and fast aggressive (one to two years in stage I). The inputs for the current model were published MCED performance measures from a large case-control study and Surveillance, Epidemiology and End Results data for persons aged 50 to 79 years for all cancer incidence.
The researchers found that under the fast tumor growth scenario, annual screening was associated with more favorable diagnostic yield. Compared with usual care, there were 370 more cancer signals detected/year/100,000 people screened, 49 percent fewer late-stage diagnoses, and 21 percent fewer deaths within five years. A similar, but less substantial, effect was seen with biennial screening compared with usual care (292 more cancer signals detected, 39 percent fewer late-stage diagnoses, and 17 percent fewer deaths within five years). For the fast tumor growth scenario, annual screening prevented more deaths within five years than the biennial scenario. However, a higher positive predictive value was seen with biennial screening (54 versus 43 percent); it was more efficient for preventing deaths within five years per 100,000 tests (132 versus 84) but prevented fewer deaths per year.
"The optimal choice of screening interval will depend on assessments of real-world cancer survival and the costs of confirmatory testing after MCED screening," the authors write.
Several authors disclosed ties to biotechnology companies, including GRAIL, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes
THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.